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Abstract 
Tumor cells display a different profile of gene expression than their normal counterparts. 
Perturbations in the levels of cellular splicing factors can alter gene expression, potentially 
leading to tumorigenesis. We found that splicing factor SRp20 (SFRS3) is highly expressed 
in cancers. SRp20 regulated the expression of Forkhead box transcription factor M1 
(FoxM1) and two of its transcriptional targets, PLK1 and Cdc25B, and controlled cell 
c y c l e   p r o g r e s s i o n   a n d   p r o l i f e r a t i o n .   C a n c e r   c e l l s   w i t h   R N A i-mediated reduction of SRp20 
expression exhibited G2/M arrest, growth retardation, and apoptosis. Increased SRp20 
expression in rodent fibroblasts promoted immortal cell growth and transformation. 
More importantly, we found that SRp20 promoted tumor induction and the maintenance 
of tumor growth in nude mice and rendered immortal rodent fibroblasts tumorigenic. 
Collectively, these results suggest that increased SRp20 expression in tumor cells is a 
critical step for tumor initiation, progression, and maintenance. 
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Introduction 
Alternative RNA splicing, a principal molecular 
event for the gene expression of approximately 70% of 
all human genes [1,2], increases the coding capacity of 
the h u m a n   g e n o m e   b y   p r o d u c i n g   d i f f e r e n t   i s o f o r m s  
from a single pre-mRNA molecule. The regulation of 
alternative  splicing  involves  interactions  between 
c e l l u l a r   s p l i c i n g   f a c t o r s   a n d   R N A   s e q u e n c e s   i n   t h e  
pre-mRNA [3,4] an d   c a n   e a s i l y   b e   p e r t u r b e d   b y   r e l a-
tively small changes in the levels of splicing factors 
[5,6].  Although  alternative  splicing  events  have  re-
cently  emerged  as  an  important  focus  in  molecular 
and clinical oncology  [7-9], the contribution of alter-
native splicing to cancer development is poorly un-
derstood. 
 S R p 2 0 ,   r e c e n t l y   r e n a m e d   a s   S F R S 3   [10],  is  a 
splicing factor that affects alternative splicing by in-
teracting with RNA cis-elements in a concentration- 
and cell differentiation–dependent manner [11,12]. It 
i s   t h e   s m a l l e s t   m e m b e r   o f   t h e   S R   p r o t e i n   f a m ily [13]. 
I n   a d d i t i o n   t o   i t s   r e g u l a t i o n   o f   R N A   s p l i c i n g ,   S R p 2 0  
plays important roles in cellular functions including 
termination  of  transcription  [14],  alternative  RNA 
polyadenylation [15], RNA export [16,17], and protein 
translation [18]. Mouse embryos lacking SRp20 do not Int. J. Biol. Sci. 2010, 6 
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form a blastocyst [19]. S R p 2 0   e x p r e s s i o n   i s   h i g h e r   t h a n  
normal in ovarian cancer s   [ 2 0 ] ;   h owever, the effect of 
this  increased  expression  is  unclear.  Overexpressed 
S R p 2 0   m i g h t   a l t e r   t h e   R N A   s p l i c i n g   a n d   o t h e r   e v e n t s  
o f   m a n y   g e n e s   i n   m a m m a lian cells, thereby substan-
tially affecting the expression levels of various protein 
isoforms [21]. Here we provide evidence that SRp20 is 
o v e r e x p r e s s e d   i n   m a n y   c a n c e r   t y p e s   a n d   t h a t   t h e   i n-
c r e a s e   i n   S R p 2 0   i s   e s s e n t i a l   f o r   c a n c e r   c e l l   s u r v i v a l   a n d  
oncogenesi s .   I n   a d d i t i o n ,   w e   f o u n d   t h a t   S R p 2 0   i s   c r i t-
ical for controlling the cell G2/M phase transition and 
for preventing cell apoptosis.  
Materials and methods         
Plasmids, cells, and tissue lysates 
 A  T7-SRp20  expression  vector  (plasmid  pJR17) 
was  constructed  b y   s w a p p i n g   t h e   T 7 -SRp20  coding 
region from a pCG-T7-SRp20 expression vector (Tom 
Misteli of NCI and Javier Caceres of Edinburgh) into 
t h e   p R e v T R E   v e c t o r   t o   p u t   T 7 -S R p 2 0   u n d e r   t h e   c o n-
trol of tetracycline. 
 Immortal  rodent  fibroblast  NIH  3T3  and  MEF 
3T3 tet-off cells (Clontech) and human C33A, 786-O, 
U2OS,  HeLa,  CaSki,  WI-38,  and  MRC-5  cells  were 
grown  in  Dulbecco’s  modified  Eagle  medium 
(DMEM,  Invitrogen)  supplemented  with  10%  fetal 
b o v i n e   s e r u m   ( F B S )   o r   c a l f   s e r u m   ( H y C l o n e ) ,   2   m M  
L-glutamine,  100  U/mL  penicillin,  and  100  μg/mL 
streptomycin. The B-cell lymphoma–derived cell lines 
BCBL-1,  JSC-1,  and  SUDHL-6  were  maintained  in 
RPMI 1640 medium (Invitrogen) supplemented with 
10%  FBS.  Primary  human  bronchial  epithelial  cells 
(HBEpiC)  and  primary  human  renal  epithelial  cells 
(HREC) were obtained and grown in medium from 
ScienCell Research Laboratories. HBEpiC were grown 
in bronchial epithelial cell medium, and HREC were 
g r o w n   i n   D M E M   s u p p l e m e n t e d   w i t h   1 0 %   F B S   a n d  
Epithelial  Cell  Growth  Supplement  (ScienCell  Re-
search  Laboratories).  Primary  newborn  human  fo-
reskin  keratinocytes  (HFKn)  were  purchased  from 
Invitrogen and grown in calcium-free Medium 154CF 
plus  human  keratinocyte  growth  supplement  (Invi-
trogen). Peripheral blood mononuclear cells were ob-
tained from healthy blood donors at the NIH Clinical 
Center blood bank. MEF 3T3 tet-o f f   c e l l s   w e r e   t r a n s-
f e c t e d   w i t h   p l a s m i d   p J R 1 7   ( T 7 -SRp20)  by  Lipofecta-
mine 2000 (Invitrogen), and selected with 200 μg/mL 
hygromycin  and  1  μg/mL  doxycycline  for  stable 
transfection.  A  cell  line  stably  transfected  with  the 
empty  vector,  pRevTRE,  was  also  established  as  a 
c o n t r o l .   T o   e x p r e s s   T 7 -SRp20,  the  stably  transfected 
MEF3T3  tet-off cells were grown in doxycycline-free 
DMEM growth medium.  
 T i s s u e   l y s a t e s   o f   v a r i o u s   p a i r s   o f   t u m o r   a n d  
ma t c h e d   n o r m a l   t i s s u e s   f r o m   d i f f e r e n t   o r g a n s   w e r e  
purchased from Protein Biotechnologies. 
RNAi 
 Synthetic,  double-stranded  siRNAs  were  ob-
tained  from  Dharmacon,  Inc.  SRp20  and  hnRNP  U 
s i R N A s   w e r e   p u r c h a s e d   a s   a n   s i G e n o m e   S M A R T p o o l  
(human SRp20, cat. No. M-030081-00; human hnRNP 
U,  cat.  No.  J-013501-00).  Human  YB-1   s i R N A   i s   a  
mixture of siRNAs 393, 394, and oJR1, as described 
[11]. T h e   n o n s p e c i f i c   ( N S )   s i R N A   h a s   5 2 %   G C   c o n t e n t  
(cat. No. D-001206-08-20).  The  SRp20  siRNA  s12732, 
targeting a splice junction of SRp 2 0   e x o n   2   a n d   e x o n   3 ,  
w a s   p u r c h a s e d   f r o m   A m b i o n   a n d   S R p 2 0   s i R N A   D -03 
was obtained separately from Dharmacon. RNAi was 
conducted by two or three separate transfections, at 
i n t e r v a l s   o f   4 8   h ,   w i t h   1 0   n M   ( A m b i o n )   o r   4 0   n M  
( D h a r m a c o n )   s i R N A   i n   t h e   p r e s e n c e   o f  Lipofectamine 
2000.  BCBL-1  and  JSC-1  lymphoma  cell  lines  were 
t r a n s f e c t e d   w i t h   4 0   n M   s i R N A   u s i n g   t h e   H i P e r f e c t  
transfection reagent (Qiagen) by three separate trans-
fections  in  accordance  with  the  instructions  of  the 
manufacturer.  The  cells  with  knocked-down  SRp20, 
YB-1 ,   o r   h n R N P   U   e x p r e s s i o n   w e r e   t h e n   a n a l y z e d   f o r  
c e l l   n u m b e r   b y   t r y p a n   b l u e   e x c l u s i o n ,   f o r   c e l l   c y c l e   b y  
f l o w   c y t o m e t r y ,   f o r   R N A   s p l i c i n g   b y   R T -PCR,  for 
protein expression by Western blotting, and for tumor 
induction by nude mouse injection. 
 HE K n   c e l l s   a t   2   ×   1 0 5 c e l l s   p e r   w e l l   i n   1 2 -well 
plates  were  transfected  4  h  after  passage  3  (day  0) 
w i t h   4 0   n M   S R p 2 0   s i R N A   o r   N S   s i R N A   b y   u s i n g   L i-
pofectamine  2000.  Cells  were  transfected  again  on 
d a y s   2   a n d   4   w i t h o u t   p a s s a g e   a n d   w e r e   c o u n t e d   o n  
day 6. HBEpiC cells at 2.5 × 105 cells per well in 6-well 
p l a t e s   w e r e   t r a n s f e c t e d   o n   d a y s   1   a n d   3   w i t h   s i R N A   a s  
d e s c r i b e d   a b o v e   f o r   H F K n   a n d   w e r e   c o u n t e d   o n   d a y  
5 .   H R E C   c e l l s   a t   2   ×   1 0 4 cells per well in 24-well plates 
w e r e   t r a n s f e c t e d   o n   d a y s   1   a n d   3   w i t h   s i R N A s   a s   d e-
scribed above for HFKn and were counted on day 5.  
Western blot 
 Protein samples in 2× SDS sample buffer were 
d e n a t u r e d   b y   b o i l i n g   f o r   5   m i n ,   s e p a r a t e d   b y   N u-
PAGE Bis-Tris gel electrophoresis (Invitrogen), trans-
f e r r e d   o n t o   a   n i t r o c e l l u l o s e   m e m b r a n e ,   a n d   b l otted 
with  the  following  antibodies:  mouse  monoclonal 
antibodies against SRp20 (7B4, American Type Cul-
ture  Collection),  beta-tubulin  (BD  PharMingen), 
h n R N P   K   ( S a n t a   C r u z   B i o t e c h ) ,   a n d   P A R P   ( C a l b i o-
chem),  or  rabbit  antibodies  against  PLK1  (Milli-
pore/Upstate), N-terminal FoxM1 (K19), and Cdc25B 
(Santa Cruz Biotech).  Int. J. Biol. Sci. 2010, 6 
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RNA preparation and RT-PCR 
 T o t a l   c e l l   R N A   w a s   p r e p a r e d   f r o m   t h e   c e l l s   u s-
ing TRIzol (Invitrogen) following the manufacturer's 
instructions.  After  DNase  I  treatment,  1  μg  of  RNA 
was reverse transcribed  at  42oC  using  random  hex-
amers  and  then  amplified  using  the  following 
gene-specific  primer  pairs:  oJR85 
(5'-CGGCTGCCCTACCTACGGA-3')  and  oJR87 
(5'-GGGAGGGCAGCTATTAGGA-3 ' )   f o r   h u m a n  
PLK1;  oJR104  (5'-CGGCTGCCCTACCTACGAA 
CG-3')  and  oJR105  (5'-  GGCACCAGTCCGAAG 
GAGAGA-3')  for  mouse  PLK1;  oJR111 
(5'-TGAAGCCACTGCTACCACG-3')  and  oJR112 
(5'-AGGGCTCTCCACTTTGATGG-3')  for  human 
FoxM1;  oJR113  (5'-TCGGCCCCGCGTGGAGCAG 
AC-3')  and  oJR114  (5'-TAACCCGATTCTGCTCC 
AGGTGAC-3')  for  mouse  FoxM1;  oJR100  (5'- 
GGGCAAGTTCAGCAACATCGTGGA-3')  and 
oJR101 (5'-GTAGCCGCCTTTCAGGATATACATC-3') 
for both human and mouse Cdc25B [22]. 
Quantitative RT-PCR (qRT-PCR) 
 Total RNA purified from cells with or without 
S R p 2 0   k n o c k d o w n   w a s   q u a n t i f i e d   b y   q R T -PCR  by 
using Applied Biosystems TaqMan probes for human 
PLK1  (#HS00983227)  and  18S  rRNA  (#4333760F)  in 
accordance  with  the  manufacturer’s  instructions. 
qRT-P C R   w a s   p e r f o r m e d   i n   a   C e p h e i d   S m a r t   c y c l e r .  
B r i e f l y ,   1   μ g   o f   t o t a l   R N A   t r e a t e d   w i t h   R N a s e -free 
DNase I was reverse transcribed at 42oC   u s i n g   r a n-
dom hexamers, followed by a 20-μL PCR reaction that 
i n c l u d e d   2   μ L   R T   p r o d u c t ,   1   μ L   T a q M a n   G e n e   E x-
pression Assays (20×), and 10 μL TaqMan Universal 
P C R   M a s t e r   m i x   ( 2 × ) .   T h e   P C R   r e a c t i o n s   w e r e   p e r-
formed at 50̊C   f o r   2   m i n   a n d   9 5 ̊C   f o r   1 0   m i n ,   f o l l o w e d  
by 40 cycles of 95̊C for 15 s and 60̊C   f o r   1 0   m i n .   T h e  
r e l a t i v e   e x p r e s s i o n   l e v e l   o f   P L K 1   i n   e a c h   s a m p l e   w a s  
c a l c u l a t e d   b y   t h e   2 -ΔΔCT or  2-ΔCT method  [23] after it 
was normalized to 18S rRNA. 
Immunohistochemical staining 
 Cervical, soft tissue, and epithelial tumors and 
n o r m a l   t i s s u e   s e c t i o n s   w e r e   p u r c h a s e d   f r o m   U S   B i o-
M a x .   I m m u n o h i s t o c h e m i s t r y   w a s   p e r f o r m e d   w i t h   a  
V e c t a s t a i n   A B C   k i t   ( V e c t o r   L a b o r a t o r i e s )   i n   a c c o r-
dance with the manufacturer's protocol. Sections were 
deparaffinized, rehydrated, and microwaved for 15 
min in the presence of 1× Antigen Retrieval Citra Plus 
buffer  (BioGenex).  Endogenous  peroxidases  were 
quenched  using  3%  hydrogen  peroxide  for  15  min. 
Sections were incubated with an anti-SRp20 7B4 an-
tibody overnight at 4̊C ,   f o l l o w e d   b y   a   s e c o n d a r y   a n-
tibody for   3 0   m i n   a n d   A B C   r e a g e n t   f o r   3 0   m i n .   T h e  
s p e c i f i c   s i g n a l   w a s   d e v e l o p e d   b y   u s i n g   a   D A B   s u b-
strate kit (Vector Laboratories). 
Colony formation assay 
 NIH 3T3 cells transiently transfected with plas-
mid  pT7-SRp20  (pJR17)  or  empty  vector 
pFLAG-CMV5.1,  or  MEF  3T3  tet-off  cells  stably 
transfected  with  plasmid  pJR17  or  empty  vector 
pRevTRE, were harvested, adjusted to 1 × 104 cells in 
DMEM  containing  0.35%  agar  and  10%  doxycyc-
line-f r e e   F B S ,   a n d   t h e n   l a i d   o n t o   a   b o t t o m   l a y e r   c o n-
taining 0.5% agar and 10% FBS in DMEM in  6-well 
plates. The plates were stained 3–4   w e e k s   l a t e r   w i t h  
0.005% crystal violet for colony counting. 
Tumor induction in nude mice  
 F o r   t u m o r   i n d u c t i o n   w i t h   H e L a   c e l l s ,   c e l l s  
t r a n s f e c t e d   t w i c e   w i t h   S R p 2 0   s i R N A   o r   n o n s p e c i f i c  
siRNAs were collected 24 h after the second transfec-
tion and implanted by dorsal subcutaneous inocula-
t i o n   o f   1   ×   1 0 6 cells into both sides of nude mice, with 
1 0   m i c e   i n   e a c h   g r o u p .   T u m o r   s i z e s   w e r e   m e a s u r e d   a t  
14, 17, and 19 days after implantation. Tumor weight 
w a s   r e c o r d e d   w h e n   t h e  animals  were  sacrificed  on 
day 22.  
 For tumor induction with MEF/3T3 tet-off cells, 
3 × 106 cells stably transfected with a T7-SRp20 vector 
o r   w i t h   t h e   e m p t y   v e c t o r   ( p R e v T R E )   w e r e   g r o w n   i n  
doxycycline-free medium and implanted as described 
above. Tumor sizes were measured every 4 to 5 days, 
and  tumor  weight  was  recorded  when  the  animals 
were sacrificed on day 50.  
Flow cytometric cell cycle analysis 
 Cell cycle distribution was determined by flow 
cytometry. U2OS or HeLa cells transfected twice with 
SRp20 siRNA or NS siRNA at an interval of 48 h were 
trypsinized  96  h  after  the  first  siRNA  transfection, 
washed  twice  with  PBS,  resuspended  in  Vindelov's 
propidium iodide buffer, and analyzed with a CYAN 
MLE  cytometer  (Dako-Cytomation).  Ten  thousand 
events  were  collected  per  sample,  and  data  were 
analyzed  with  Modfit  LT  software  (Verity  Software 
House). 
 T o   a n a l y z e   t h e   s y n c h r o n i z e d   c e l l s   f o r   c e l l   c y c l e  
progression, MEF 3T3 tet-off  cells  stably  transfected 
with T7-SRp20x were seeded in a 6-w e l l   p l a t e   a t   5   ×  
104 cells per well in DMEM containing 10% doxycyc-
line-free  FBS  overnight,  synchronized  by  starvation 
f o r   4 8   h   i n   D M E M   c o n t a i n i n g   0 . 1 %   F B S ,   a n d   t h e n   c o l-
lected at the indicated times after serum stimulation 
(with 10% FBS) for cell cycle analysis by flow cyto-
metry as described above.  Int. J. Biol. Sci. 2010, 6 
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Oncomine cancer microarray database analyses 
 The  Oncomine  cancer  microarray  database 
[http://www.oncomine.com; [24]]  was used to ana-
l y z e   e x p r e s s i o n   p r o f i l e s   o f   S R p 2 0   i n   a   v a r i e t y   o f   h u-
man cancerous and normal tissues and in association 
with tumor progression (grade) and 5-year survival 
rate. Statistics from individual studies were also ob-
tained from the Oncomine cancer database (January 
15 or April 15, 2010, version) and were combined for a 
Fisher’s meta-analysis. Overexpression of SRp20 was 
defined as significantly higher expression (P < 0.05) in 
t u m o r   t i s s u e s   t h a n   i n   t h e   c o r r e s p o n d i n g   n o r m a l   t i s-
sues, in high-g r a d e   t u m o r s   t h a n   i n   l o w -grade tumors, 
or in shorter-living (<5 years) cancer patients than in 
longer-living (>5 years) cancer patients. 
Southern blot and semi-quantitative PCR analy-
sis 
 S o u t h e r n   b l o t   a n a l y s i s   w a s   c o n d u c t e d   b y   u s i n g  
~5 μg of EcoRI-digested genomic DNA extracted from 
paired normal and cancerous lung tissues (BioChain 
Institute ,   H a y w a r d ,   C A )   a n d   h y b r i d i z e d   w i t h   a n  
SRp20 DNA probe, a 649-bp PCR fragment amplified 
with  a  5'  primer  (oJR53,  5'-AAGCCGTCCCGA 
TCCTTCTC-3')  and  a  3'  primer  (oJR57, 
5'-GACTGCTTGTTCAACTATAGCTGCA-3')  from 
HeLa genomic DNA and randomly labeled with 32P. 
The  blot was reprobed for cyclophilin as a loading 
control by using a cyclophilin probe, a 660-bp  frag-
ment  derived  from  a  Hind  III-digested  1.1-kb  PCR 
product  amplified  w i t h   a   5 '   p r i m e r   ( o S B 2 1 ,  
5'-CCAAAGCATTGTACCGCAGAG-3') and  a 3'  pri-
mer  (oSB22,  5'-TTGCATATACTGCCTTCTCTT 
TATC-3 ' )   f r o m   H e L a   g e n o m i c   DNA  and  randomly 
labeled with 32P. 
 For  semi-quantitative  PCR  analysis  of  SRp20 
gene  amplification  in  paired  normal  and  cancerous 
c e r v i c a l   o r   l u n g   t i s s u e s ,   g e n o m i c   D N A   i s o l a t e d   f r o m  
the cervical or lung tissues was serially  diluted  and 
a n a l y z e d   b y   P C R   b y   u s i n g   a   p r i m e r   p a i r   o f   o J R 5 6  
(5'-TCTCTTGAAACAGTGACACAAAGGTG-3')  and 
oJR57 for SRp20 gene detection. Cyclophilin PCR with 
a   p r i m e r   p a i r   o f   o S B 2 1   a n d   o S B 2 2   s e r v e d   a s   l o a d i n g  
control. 
Statistical analysis 
 Statistical  data for the paired microarray data-
s e t s   i n   F i g .   3 ,   w e r e   o b t a i n e d   d i r e c t l y   f r o m   t h e   O n c o-
mine cancer database (www.oncomine.com). Statistics 
from individual studies with significantly higher ex-
pression of SRp20 (P < 0.05) in  tumor  tissues  than  in 
the corresponding normal tissues were also obtained 
from the Oncomine cancer database (January 15 or 
A p r i l   1 5 ,   2 0 1 0 ,   v e r s i o n )   a n d   w e r e   c o m b i n e d   f o r   F i s h-
er’s meta-analysis. All two-group statistical compari-
s o n s   o f   m e a n s   i n   F i g .   6   a n d   F i g .   1 0   w e r e   c a l c u l a t e d  
with  two-tailed  student’s  t  test  using  Excel  (Micro-
soft). 
Results 
Increased SRp20 expression in epithelial carci-
nomas and mesenchymal tissue–derived sarco-
mas  
 In looking at the role of SRp20 in human papil-
lomavirus (HPV) RNA splicing [11],   w e   f o u n d   a   r e-
markable  inc r e a s e   o f   S R p 2 0   e xpression  in  cervical 
cancer tissues (Fig. 1A). However, this increase was 
not limited to cancers caused by HPV infection. We 
also observed variable increases of SRp20 expression 
in   c a n c e r s   o f   t h e   l u n g ,   b r e a s t ,   s t o m a c h ,   s k i n ,   b l a d d e r ,  
col o n ,   l i ve r ,   t h y r oid, and kidney (Fig. 1B), as well as in 
B-cell lymphoma cells (JSC-1  [KSHV+/EBV+],  BCBL1 
[KSHV+], and SUDHL-6; Fig. 1C).  
 
 
Fig. 1 SRp20 expression in   t u m o r   ( T )   a n d   n o r m a l   ( N )   t i s s u e s   b y  
Western blot analysis. Tissue samples (A and B)   o r   l y m p h o m a   B   c e l l s  
(C) were immunoblotted with an anti-SRp20 7B4 antibody; hnRNP 
K   a n d   t u b u l i n   s e r v e d   a s   c o n t r o l s   f o r   s a m p l e   l o a d i n g .   P B M C ,   p e r i-
pheral blood mononuclear cells.  
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Tissue-array  immunohistochemistry  demon-
s t r a t e d   i n c r e a s e d   e x p r e s s i o n   o f   S R p 2 0   n o t   o n l y   i n   e p-
ithelial carcinomas (Fig. 2), but also in mesenchymal 
tissue–derived  tumors,  including  rhadbomyosar-
coma,  hemangioendothelioma,  hemangiopericyto-
ma,  neurofibroma,  neurilemmoma,  liposarcoma, 
leiomyosarcoma,  histiocytoma,  and  synovial  sar-
coma  (Supplementary  information,  Fig.  S1).  By 
searching the Oncomine cancer microarray database 
(http://www.oncomine.com),  we  found  a  signifi-
cant increase (P <   0 . 0 5 )   o f   S R p 2 0   e x p r e s s i o n   i n   t u m o r  
tissues over the expression in corresponding normal 
tissues in 96 of 190 studies. Fisher’s meta analysis 
indicated that the observed increase in those paired 
studies was significant (P  <0.001).  We  also  found 
t h a t   t h e   i n c r e a s e d   S R p 2 0   e x p r e s s i o n   c o r r e l a t e d   w i t h  
b r e a s t   c a n c e r   p r o g r e s s i o n   i n   1 3   o f   2 6   s t u d i e s  
(P<0.001) as represented in Fig. 3A [25,26], and with 
5-year overall survival in 3 of 6 studies (P = 0.001), 
as represented in Fig. 3B [27,28]. 
 
 
Fig. 2 Expression of SRp20 in tumor and normal tissues 
by  immunohistochemistry.  All  tissue  sections  were 
stained with the SRp20 7B4 antibody and counterstained 
with  Mayer's  hematoxylin.  Boxes  in  the  low-
er-magnification images (×20) indicate locations where 
the higher-magnification  images  (×40)  were  taken.  Ar-
rows in the ×40-magnification images indicate individual 
cells further magnified on the right. (A) Squamous cell 
c a r c i n o m a   ( g r a d e   I I I )   o f   c e r v i x   a n d   n o r m a l cervical tissues. 
N o r m a l   c e r v i c a l   t i s s u e s   e x p r e s s   a   l o w   l e v e l   o f   S R p 2 0   i n  
terminally  differentiated  cells,  but  a  medium  level  of 
SRp20 in dividing basal or parabasal cells. In contrast, all 
cervical cancer cells show abundant SRp20 expression, 
with strong nuclear staining of SRp20 (see individual cells 
on the right). (B) Alveolar rhabdomyosarcoma of right 
shoulder  and  normal  striated  muscle.  Rhabdomyosar-
coma  cells  express  high  levels  of  SRp20,  but  normal 
striated muscle tissues show no detectable SRp20. (C) 
Esophageal small-cell carcinoma and normal esophagus. 
All cancer cells show strong nuclear staining for SRp20, 
but only the dividing basal or parabasal cells in normal 
esophagus expressed SRp20 at a medium level. 
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 As the gene SFRS3 which  encodes  SRp20 is lo-
c a t e d   o n   c h r o m o s o m e   6 p 2 1 ,   a   c o m m o n   r e g i o n   o f   D N A  
amplification seen in many cancers [29], we examined 
w h e t h e r   g e n e   a m p l i f i c a t i o n   w o u l d   b e   a   c a u s e   f o r   i n-
creased SRp20 expression in cancer tissues. As shown 
in Fig. 4, we verified SFRS3 gene amplificatio n   i n   l u n g  
cancer  by  Southern  blotting  and  semi-quantitative 
P C R   a n d   i n   c e r v i c a l   c a n c e r s   b y   s e m i -quantitative PCR, 
demonstrating  that  SFRS3  gene amplification could 
b e   a   c a u s e   o f   i n c r e a s e d   S R p 2 0   e x p r e s s i o n   i n   a t   l e a s t   a  
subset of these cancers. 
 
 
Fig. 3. SRp20 association with tumor progression and prognosis. (A)   I n c r e a s e d   e x p r e s s i o n   o f   S R p 2 0   c o r r e l a t e s   w i t h   t u m o r  
grade in breast cancer in studies by Schmidt et al. [left; [25]] and Sotiriou et al. [right; [26]]   a s obtained from the Oncomine 
cancer database (January 15, 2010, version). (B) Breast cancer patients who survived less than 5 years expressed a higher 
l e v e l   o f   S R p 2 0   i n   t h e i r   t u m o r   t i s s u e s   t h a n   t h o s e   w h o   l i v e d   l o n g e r .   D a t a   a n d   s t a t i s t i c s   w e r e   c o m p i l e d   f r o m  the studies of Bild 
et al. [left; [27]] and Boersma et al. [right; [28]], also obtained from the Oncomine cancer database (January 15, 2010, 
version).  Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
812 
 
Fig. 4. SRp20 gene amplification in tumor tissues. (A) Southern blot analysis of SRp20 gene amplification in paired normal 
and cancerous lung tissues. The level of SRp20 relative to cyclophilin DNA is expressed below the blot as a ratio, with the 
ratio set to 1 for the normal tissue. (B) Semi-quantitative PCR analysis of SRp20 gene amplification in paired normal and 
cancerous cervical and lung tissues. (C)   T h e   r e l a t i v e   i n t e n s i t y   ( x   1 0
3)   o f   e a c h   P C R   a m p l i c o n   i n   ( B)   w a s   n o r m a l i z e d   t o  
cyclophilin as a control for sample loading. 
 
 
SRp20 is required for cell proliferation because it 
promotes the G2/M transition 
 Increased  SRp20  could  potentially  induce  the 
production of mRNA isoforms that encode proteins 
favoring oncogenesis. We therefore hypothesized that 
increased  SRp20  expression  might  contribute  to 
maintenance  of  the  carcinogenic  phenotype,  rather 
t h a n   b e i n g   a   c o n s e q u e n c e   o f   i t .   T o   t e s t   t h i s   p o s s i b i l i t y ,  
we  examined  whether  reduced  SRp20  expression 
w o u l d   a f f e c t   c a n c e r   c e l l   g r o w t h .   E a c h   o f   s e v e n   c a n c e r  
cell  lines  (U2OS,  HeLa  [HPV18+],  CaSki  [HPV16+], 
C33A,  786-O,  JSC-1, and BCBL-1) exhibited reduced 
proliferation  after  SRp20  expression  was  knocked 
d o w n   b y   a n   s i R N A   p o o l   t a r g e t i n g   d i f f e r e n t   r e g i o n s   o f  
SRp20  mRNA  (Fig.  5A-C,  Supplementary  informa-
tion, Fig. S2A-E ) .   T o   e x c l u d e   a n y   p o s s i b l e   o f f -target 
e f f e c t   o f   t h e   p o o l e d   S R p 2 0   s i R N A s ,   we  performed 
similar experiments in U2OS and HeLa cells by using 
a separate siRNA, siRNA s12732, that targets a splice 
junction  of  SRp20  exon  2  and  exon  3  (Fig.  5A)  and 
observed the same results (Fig. 5D-E). Using siRNA 
D-03 alone in U2OS cells also gave the same result 
(Supplementary  information,  Fig.  S2F).  By  contrast, 
knockdown  of  YB-1   o r   h n R N P   K   h a d   n o   e f f e c t   o n  
HeLa  cell  growth  (Supplementary  information,  Fig. 
S 2 G ) .   F u r t h e r   s t u d i e s   s h o w e d   t h a t   k n o c k d o w n   o f  
SRp20 expression in U2OS cells led to cell apoptosis, 
as indicated by apoptotic cleavage of PARP (Fig. 5F). 
These data indicate that increased SRp20 expression is 
n e c e s s a r y   f o r   t h e   i n d e f i n i t e   g r o w t h   o f   c a n c e r   c e l l s   a n d  
prevents cancer cell apoptosis.  
WI-38 and MRC-5 cells, two human diploid lung 
fibroblast cell lines with a finite lifetime of about 50 
population  doublings,  naturally  express  much  less 
SRp20 than U2OS and HeLa cells (Fig. 6A). 
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Fig. 5 I n c r e a s e d   S R p 2 0   i s   e s s e n t i a l   f o r   t u m o r   c e l l   g r o w t h .   ( A) Schematic illustration of siRNA target sites in the SRp20 open 
reading frame (ORF). Arrows represent individual exons and translation directions. Bars above arrows are relative positions 
o f   s i R N A   t a r g e t   s i t e s   a l o n g   w i t h   t h e   s i R N A   n a m e s .   D -01, D-0 2 ,   D -03, and D-0 4   a r e   f o u r   d i f f e r e n t   s i R N A s   i n   a n   s i R N A   p o o l  
from Dharmacon. siRNA s12732, which spans the exon 2/exon 3 junction of SRp20 mRNA was from Ambion. (B-E) 
K n o c k d o w n   o f   S R p 2 0   e x p r e s s i o n   a f f e c t s   c a n c e r   c e l l   p r o l i f e r a t i o n .   S R p 2 0   w a s   k n o c k e d   d o w n   i n   U 2 O S   c e l l s   ( a n   o s t e o s ar-
coma cell line with wild-type p53 and pRb) and HeLa cells (an HPV18
+ cervical cancer cell line) by the Dharmacon siRNAs 
(40 nM, B-C) or Ambion siRNA s12732 (10 nM, D-E). Insets show SRp20 knockdown efficiency in monolayer cultures by 
Western blot on day 2 (D2, B-C)   a n d   d a y   4   ( D 4 ,   B-E) after RNAi. Arrows indicate the days the cells received siRNA 
treatments. Below the line graphs of B and C are crystal violet staining of the corresponding cells after RNAi. NS, non-
s p e c i f i c   s i R N A .   ( F) SRp20 knockdown-mediated cell apoptosis. Poly(ADP-ribose) polymerase (PARP) cleavage was analyzed 
by Western blot as an apoptotic biomarker [61] in U2OS cells after SRp20 knockdown with the indicated siRNAs in A.  Int. J. Biol. Sci. 2010, 6 
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Fig. 6. Human diploid fibroblasts and primary human epithelial cells express minimal amounts of SRp20. (A) MRC-5 and 
WI-38 fibroblasts express less SRp20 than U2OS and HeLa cells by Western blot analysis. Tubulin served as a control for 
s a m p l e   l o a d i n g .   ( B) Ectopic expression of SRp20 in WI-38 cells promotes cell growth. WI-38 cells were transfected during 
cell passage on days 0, 2, and 4 with 2 μg of T7-SRp20 plasmid and were counted on day 6. Shown immediately below the Int. J. Biol. Sci. 2010, 6 
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c o r r e s p o n d i n g   b a r   g r a p h   a r e   c e l l   l y s a t e s   b l o t t e d   w i t h   S R p 2 0   a n t i b o d y   7 B 4 .   D a t a   a r e   s h o w n   a s   m e a n s   ±   S E   f r o m   t w o   s e p a r a t e  
experiments, each performed in duplicate. (C) Western blot comparison of primary HFKn, HBEpiC, and HREC cells with 
H e L a ,   U 2 O S ,   C a S k i ,   a n d   C 3 3 A   c e l l s   f o r   S R p 2 0   e x p r e s s i o n   b y   W e s t e r n   b l o t .   T u b u l i n   o r   h n R N P   K   s e r v e d   a s   a   c o n t r o l   f o r  
sample loading. (D-F) Knockdown of SRp20 expression in HFKn (D), HBEpiC (E), and HREC (F) cells affects cell growth. 
Western blots above each bar graph show the knockdown efficiency of SRp20 by siRNA. The g r a p h   s h o w   m e a n s   ±   S E   f r o m  
at least two separate experiments, each in duplicate. 
 
 
 When  SRp20  was  transiently  introduced  into 
WI-3 8   c e l l s ,   t h e   c e l l   g r o w t h   i n c r e a s e d   ( F i g .   6 B ) .   I n t e-
restingly,  human  primary  epithelial  cells  (human 
newborn  foreskin  keratinocytes  [HFKn],  human 
bronchial epithelial cells [HBEpiC], and human renal 
epithelial cells [HREC]), which have limited doubling 
times in culture, also express less SRp20 than cancer 
c e l l   l i n e s   ( F i g .   6 C ) .   K n o c k i n g   d o w n   S R p 2 0   e x p ression 
i n   t h e s e   c e l l s   a l s o   s l o w e d   t h e i r   g r o w t h   ( F i g .   6 D -F). 
A l t o g e t h e r ,   t h e s e   d a t a   i n d i c a t e   t h a t   S R p 2 0   i s   a l s o   e s-
sential for normal cell proliferation. 
 Flow  cytometry  showed  that  both  U2OS  and 
H e L a   c e l l s   w i t h   s i R N A -mediated reduction of SRp20 
displayed pr o m i n e n t   G 2 / M   a r r e s t   ( F i g .   7 A ) ,   a c c o m-
p a n i e d   b y   i n c r e a s e d   e x p r e s s i o n   o f   F o x M 1 a   a n d   d e-
creased  expression  of  FoxM1b-c,  Cdc25B  [30],  and 
polo-like  kinase-1  (PLK1;  [31]  at  the  mRNA  level   
(Fig.  7B,  Supplementary  information,  Fig.  S3).  We 
noticed that U2OS cells which contain a functional G1 
check-point  [32],  but  not  HeLa  cells  which  lack  a 
functional G1 check-p o i n t   d u e   t o   H P V 1 8   E 7   d e g r a d a-
tion of pRb [33], a l s o   a p p e a r e d   a   s l i g h t   i n c r e a s e   o f   c e l l  
number  at  S  phase  after  knocking  down  SRp20  ex-
pression (Fig. 7A). Western blotting analyses showed 
reduced protein expression of FoxM1b-c, Cdc25B, and 
P L K 1   ( F i g .   7 C ) ,   w h i c h   a r e   a l l   i n v o l v e d   i n   t h e   G 2 / M  
transition  [34-36]. Because the physiological signific-
a n c e   o f   F o x M 1 a   i s   n o t   c l e a r   a n d   i t   i s   n o t   g e n e r a l l y   d e-
tectable by Western blot [37,38], we conclude that the 
i n c r e a s e d   e x p r e s s i o n   o f   S R p 2 0   i n   c a n c e r   c e l l s   p r o-
motes cell cycle progression by affecting the expres-
sion of G2/M transition regulators, thus contributing 
t o   t h e   i n d e f i n i t e   g r o w t h   o f   t h e   t u m o r   c e l l   l i n e s   i n  
monolayer culture.  
Increased SRp20 expression promotes immortal 
cell growth and transformation 
 When  ectopically  expressed  in  immortal  NIH 
3 T 3   f i b r o b l a s t s   i n   t h e   p r e s e n c e   o f   e n d o g e n o u s   S R p 2 0 ,  
T7-tagged human SRp20 (T7-SRp20) conferred a sub-
stantial growth advanta g e   t o   c e l l s   i n   m o n o l a y e r   c u l-
ture (Fig. 8A) and anchorage-independent growth to 
c e l l s   i n   s o f t   a g a r   ( F i g .   8 B ) .   T h i s   e x p e r i m e n t   w a s   r e-
p e a t e d   i n   a n o t h e r   i m m o r t a l   c e l l   l i n e ,   S w i s s   M E F  
(mouse embryonic fibroblast) 3T3 cells. The cells with 
t r a n s i e n t   ( F i g .   8 C )   o r   s t a b l e   e x p r e s s i o n   ( F i g .   8 D )   o f  
T7-SRp20  displayed  a  two-fold  increase  in  growth 
rate; colony formation in soft agar also increased (Fig. 
8E-F).  
 Knockdown of SRp20 expression in cancer cells 
reduced  the  expression  of  the  cell  cycle  regulators 
FoxM1,  Cdc2 5 B ,   a n d   P L K 1   a n d   p r e v e n t e d   c e l l   c y c l e  
progression through G2/M phase (Fig. 7); in contrast, 
expression of T7-SRp20 in stably transfected MEF 3T3 
cells in the presence of endogenous SRp20 enhanced 
the expression of FoxM1, Cdc25B, and PLK1 both at 
t h e   R N A   ( F i g .   8 G )   a n d   p r o t e i n   ( F i g .   8 H )   l e v e l s   a n d  
accelerated  cell  cycle  progression  of  synchronized 
MEF 3T3 tet-o f f   c e l l s .   A s   s h o w n   i n   F i g .   9 ,   o v e r e x p r e s-
sion  of  T7-S R p 2 0   i n   s y n c h r o n i z e d   M E F   3 T 3   t e t -off 
cells pushed the cells quickly go through G2/M phase 
(compare c e l l   n u m b e r s   a t   G 2 / M   p h a s e   f r o m   7   h   t o   1 0  
h)  and  accelerated  the  cell  cycle  transition  from 
G0/G1 to S phase (compare cell numbers at G0/G1 
a n d   S   p h a s e   f r o m   1 0   h   t o   1 5 h ) ,   o v e r   t h e   v e c t o r   c o n-
trols. 
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Fig. 7. SRp20 regulates expression of FoxM1, Cdc25B, and PLK1 and is essential for cell cycle progression. (A) U2OS and 
H e L a   c e l l s   w i t h   S R p 2 0   k n o c k e d   d o w n   b y   R N A i   w e r e   c o l l e c t e d   f o r   f l o w   c y t o m e t r y .   N S ,   n o n -specific siRNA. One repre-
sentative of two separate experiments is shown. (B and C) SRp20 regulates expression of FoxM1, Cdc25B, and PLK1. U2OS 
a n d   H e L a   c e l l s   w i t h   S R p 2 0   k n o c k d o w n   a s   d e s c r i b e d   i n   F i g .   3   w e r e   e x a m i n e d   f o r   F o x M 1 ,   C d c 2 5 B ,   a n d   P L K 1   e x p r e s s i o n   a t   t h e  
R N A   l e v e l   b y   R T -PCR (B) and at the protein level by immunoblot (C). Diagrams to the right of B show RNA splicing 
d i r e c t i o n s   o f   F o x M 1 ,   C d c 2 5 B ,   a n d   P L K 1   a n d   p r i m e r   p o s i t i o n s   ( s h o r t   l i n e s   a b o v e   o r   b e l o w   e x o n s   [ b o x e s ] )   f o r   R T -PCR; 
relative expression levels of each RNA transcript after being normalized to GAPDH are indicated underneath the gels. RT, 
reverse transcription. Protein levels of SRp20, FoxM1, Cdc25B, and PLK1 were also measured by Western blot (C); 
GAPDH (B) and hnRNP K (C) served as controls for sample loading in each assay. Int. J. Biol. Sci. 2010, 6 
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Fig. 8. Overexpression of SRp20 promote s   c e l l   g r o w t h   a n d   t r a n s f o r m a t i o n .   ( A and B) Transient expression of T7-SRp20 in 
t h e   p r e s e n c e   o f   e n d o g e n o u s   S R p 2 0   i n   N I H   3 T 3   c e l l s   p r o m o t e s   c e l l   g r o w t h   ( A)   a n d   c o l o n y   f o r m a t i o n   i n   s o f t   a g a r   ( B), with 
the colonies at the top seen under a stereomicroscope at the same magnification for both photos. Arrows indicate the days 
the cells were transfected with a T7-SRp20 or empty vector. (C-F) Transient (C) or stable (D-F) expression of T7-SRp20 
in the presence of endogenous SRp20 in MEF 3T3 tet-o f f   c e l l s   p r o m o t e s   c e l l   g r o w t h   ( C and D) and colony formation (E and 
F) .   I n s e t s   i n   A, C,   a n d   D are expressed T7-SRp20 and endogenous SRp20 by Western blot on day 4. Representative images 
o f   c o l o n i e s   i n   s o f t   a g a r   ( E) show two stable cell lines with (top) or without (bottom) T7-SRp20 expression. Colony counts 
i n   t w o   s e p a r a t e   e x p e r i m e n t s   f r o m   t w o   d i f f e r e n t   s t a b l e   c e l l   l i n e s   w i t h   o r   w i t h o u t   T 7 -SRp20 expression are graphed (F), with 
the colonies at the top seen under a stereomicroscope at the same magnification for both photos. (G and H) stable ex-
pression of T7-SRp20 in the presence of endogenous SRp20 in MEF 3T3 tet-off cells promotes the expression of FoxM1, 
C d c 2 5 B ,   a n d   P L K 1   a s   d e t e c t e d   w i t h   R T -P C R   f o r   R N A s   ( G)   a n d   w i t h   i m m u n o b l o t t i n g   f o r   p r o t e i n s   ( H) .   D i a g r a m s   o n   t h e   r i g h t  
of G show the primer positions (short lines above or below exons [boxes]). RT, reverse transcription. GAPDH (G) and 
hnRNP K (H) served as controls for sample loading in each assay. Int. J. Biol. Sci. 2010, 6 
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Fig.  9. Stable expression of T7-SRp20 in 
MEF 3T3 tet-off cells promotes cell cycle 
progression. MEF 3T3 tet-off cells stably 
transfected with a T7-SRp20 vector or an 
empty  vector  were  grown  in  doxycyc-
line-free medium, synchronized by starva-
tion for 48 h, and collected after the indi-
cated  durations  of  serum  stimulation  for 
cell cycle flow cytometry. One represent-
ative  of  two  separate  experiments  is 
shown. 
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Increased SRp20 expression is required for tu-
mor induction and maintenance in nude mice 
 Given  the  cell  growth  and  transformation  po-
tential of SRp20, we conducted a series of nude mouse 
s t u d i e s   o n   S R p 2 0   o n c o g e n e s i s .   M u c h   l o w e r   t u m o r  
induction  was  seen  when  HeLa  cells  with             
siRNA-reduced  SRp20  expression  were  implanted 
into  nude  mice  than  when  HeLa  cells  receiving  a 
nonspecific  siRNA  were  implanted  (Fig.  10A-C). 
When implanted into nude mice, MEF 3T3 cells with 
stable  T7-SRp20 expression in the presence of endo-
g e n o u s   S R p 2 0   e x h i b i t e d   l a r g e   t u m o r s ,   w h e r e a s   t h e  
cells  stably  transfected  with  the  control  vector  were 
not  competent  for  tumorigenesis  (Fig.  10D-F).  To-
gether, these data indicate that increased SRp20 ex-
pression in immortalized, untransformed mammalian 
cells is also oncogenic in nude mice. 
 
 
Fig. 10. SRp20 overexpression is tumorigenic in nude mice. (A-B) HeLa cells with reduced SRp20 expression are less 
c o m p e t e n t   a t   i n d u c i n g   t u m o r s .   H e L a   c e l l s   ( 1   ×   1 0
6) with or without SRp20 knockdown were implanted subcutaneously, and 
the tumor diameter (A) was measured on the indicated days. The tumor weight (B) was recorded when the animals were 
sacrificed on day 22. Data are means ± SE from 10 animals in each group (P < 0.01 for tumor size at each time point and P 
< 0.05 for tumor weight, t test). (C)   T u m o r s   f r o m   H e L a   c e l l s   t r e a t e d   w i t h   N S   o r   S R p 2 0   s i R NAs and implanted into both 
sides of the mice (L, left; R, right). Tumors from five animals from each group are shown. (D-E) MEF 3T3 tet-off cells with 
SRp20 overexpression are tumorigenic. MEF 3T3 tet-o f f   c e l l s   ( 3   ×   1 0
6) stably transfected with an empty vector only or a 
T7-SRp20 vector were grown in doxycycline-free medium and then implanted subcutaneously, and the tumor diameter (D) 
and weight (E) were measured as described above. Data are means ± SE from 5 animals in each group (P < 0.001 for both Int. J. Biol. Sci. 2010, 6 
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tumor size at each time point and weight). (F)   T u m o r s   f r o m   M E F 3 T 3   t e t -off cells with or without T7-SRp20 expression 
implanted into the left or right side. (G) A model for SRp20 regulation of cell cycle progression and tumorigenesis. SRp20 
regulates the expression of FoxM1, Cdc25B, and PLK1 and controls cell apoptosis. Green ovals: cells; orange circles: nuclei; 
bars: genomes. 
 
 
Discussion 
 Although  various  efforts  have  been  made  to 
u n d e r s t a n d   t h e   m o l e c u l a r   b a s i s   o f   t u m o r i g e n esis, the 
mechanisms that lead to tumor-specific gene expres-
sion remain largely unknown. Altered expression of 
splicing factors had been described in various tumor 
types [9,20,39-41], but the effect of increased expres-
s i o n   o f   s p l i c i n g   f a c t o r s   o n   t u m o r i g e n e sis remained to 
b e   i n v e s t i g a t e d .   T o   o u r   k n o w l e d g e ,   t h e r e   h a s   b e e n   n o  
r e p o r t   o n   t h e   r o l e   o f   S R p 2 0   i n   t h e   d e v e l o p m e n t   o f  
c a n c e r .   I n   t h i s   s t u d y ,   w e   d e m o n s t r a t e d   a   d i r e c t  
cause–effect  relationship  between  increased  SRp20 
expression  and  tumor  formation  with  the following 
evidence: First, all cancer types examined exhibited 
i n c r e a s e d   S R p 2 0   e x p r e s s i o n .   S R p 2 0   e x p r e s s i o n   i n  
breast cancer tissues increased with cancer progres-
sion  and  correlated  with  patients’  5-year  survival. 
Second, cancer cells with reduced SRp20 expression 
appear to grow slowly, undergo apoptosis as reported 
while our manuscript was in preparation [42], and are 
less tumorigenic in nude mice. Third, overexpression 
of SRp20 in immortal 3T3 cells caused cell transfor-
mation and induced tumor formation  in  nude  mice. 
We  characterize  SRp20  as  a  novel  proto-oncogene 
b e c a u s e   S R p 2 0   i s   a   n o r m a l   c e l l u l a r   g e n e   t h a t ,   w h e n  
expressed  at  its  physiological  level,  is  essential  for 
n o r m a l   c e l l   p r o l i f e r a t i o n   i n   c u l t u r e s   ( F i g .   6 ) .   T h e   c e l l s  
in the basal layers of cervix and esophagus, which are 
d i v i d i n g   c e l l s ,   a p p e a r   t o   e x p r e s s   S R p 2 0   r e l a t i v e l y  
more  than  non-dividing,  terminally  differentiated 
cells (Fig. 2). Together with the finding that splicing 
factor  SF2/ASF  is  overexpressed  in  lung  and  colon 
cancers and is oncogenic in nude mice  [9],  our data 
provide compelling evidence that altered expression 
o f   S R   p r o t e i n s   i s   a n   i m p o r t a n t   c o n t r i b u t o r   t o   t h e   d e-
velopment of cancer. 
 SRp20  that  becomes  oncogenic  appears  only 
w h e n   i t s   e x p r e s s i o n   f r o m   c h r o m o s o m e   6 p   i s   i n-
creased,  presumably  by  gene  amplification.  This 
chromosome region bearing the SFRS3 (SRp20)  gene 
i s   c o m m o n l y   a m p l i f i e d   i n   m a n y   c a n c e r s  [29].  Our 
preliminary  investigation  has  confirmed  that  gene 
amplification could be a cause of SRp20 overexpres-
sion in lung and cervical cancers (Fig. 4). Other onco-
genic  signaling  pathways  might  also  trigger  SRp20 
expression. One such pathway might be the Wnt sig-
naling pathway, which is implicated in driving the 
formation of various human cancers and recruits cy-
tosolic β-catenin as a transcriptional coactivator [43] to 
transactivate  SRp20  expression  [44].  Although  the 
s p e c i f i c   c a u s e   o f   i n c r e a s e d   S R p 2 0   e x p r e s s i o n   i n   h u-
man  cancers  remains  to  be  investigated,  and  there 
may be several possible causes, SFRS3 gene amplifi-
cation in chromosome 6p as reported in many other 
studies [29] may lead to increased SRp20 expression 
in at least a subset of these cancers. 
 The dysregulated expression of splicing factors 
can  change  general  RNA  splicing  and  other  events 
essential  for  the  proper  expression  of  the  targeted 
genes, consequently causing diseases and tumor for-
mation [8,45-47]. In this report, we identified cellular 
F o x M 1 ,   P L K 1 ,   a n d   C d c 2 5 B   a s   t h r e e   p r o m i n e n t   t a r g e t s  
of SRp20 in the regulation of cell proliferation and 
oncogenesis (Fig. 10G). FoxM1, known previously as 
HFH-11, WIN, MPP-2, FKHL-16, or Trident [48], is a 
transcription factor of the Forkhead family that regu-
l a t e s   e x p r e s s i o n   o f   P L K 1 ,   C d c 2 5 B ,   and  CENP-F 
[34,49-51]. FoxM1 is expressed in proliferating cells in 
a  cell  cycle–dependent  manner  [37,52-54] and plays 
crucial  roles  in  the  G2/M  transition  [49,50]  and  in 
chromosome stability and segregation during mitosis 
[34].  The  gene  encoding  FoxM1  on  chromosome 
12p13.3  produces  a  primary  transcript  that  can  be 
alternatively  spliced  to  create  three  RNA  species by 
i n c l u s i o n   ( F o x M 1 a   a n d   1 c )   o r   e x c l u s i o n   ( F o x M 1 b )   o f  
exon 6 and inclusion (FoxM1a) or exclusion (FoxM1b 
and  1c)  of  exon  9  (Supplementary  information,         
Fig. S3); these three RNA species produce three pro-
tein isoforms, FoxM1a, 1b, and 1c, with only FoxM1b 
and 1c being transcriptionally active [48]. Two FoxM1 
t a r g e t s ,   P L K 1   a n d   C d c 2 5 B ,   a r e   c r u c i a l   f o r   e n t r y   o f   t h e  
cell cycle into mitosis [31,55,56], are all overexpressed 
in many cancers and oncogenic [48,55,57,58] and were 
all  expressed  at  reduced  levels  in  U2OS  and  HeLa 
c e l l s   w i t h   S R p 2 0   k n o c k d o w n ,   c a u s i n g   t h e   c e l l s   t o   a r-
r e s t   a t   G 2 / M .   B e c a u s e   P L K 1 -dependent  phosphory-
l a t i o n   o f   F o x M 1   i s   r e q u i r e d   f o r   G 2 / M   p r o g r e s s i o n 
[59], r e d u c e d   P L K 1   e x p r e s s i o n   i n   t h e   c e l l s   w o u l d   r e-
sult in nonfunctional FoxM1, thereby exaggerating the 
FoxM1  deficiency  caused  by  SRp20  knockdown.  In 
c o n t r a s t ,   o v e r e x p r e s s i o n   o f   S R p 2 0   i n   3 T 3   c e l l s   s t i m u-
l a t e d   t h e   e x p r e s s i o n   o f   F o x M 1   a n d   i t s   t a r g e t s   P L K 1  
a n d   C d c 2 5 B   a n d   p r o m o t e d   c e l l   p r o l i f e r a t i o n   a n d   t u-
morigenesis.  Int. J. Biol. Sci. 2010, 6 
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 Although the mechanis m   b y   w h i c h   S R p 2 0   p r o-
motes FoxM1 expression remains to be determined, 
we assume that SRp20 regulation of FoxM1 expres-
sion  is  both  transcriptional  and  posttranscriptional. 
Because SP1 binding to the FoxM1 promoter regulates 
FoxM1  expression  [60],  downregulat i o n   o f   S P 1   e x-
pression in cells with reduced SRp20 levels [11] may 
be responsible for FoxM1 reduction at the transcrip-
t i o n a l   l e v e l .   H u m a n   F o x M 1   e x o n   9   i s   n o t   c o n s e r v e d   i n  
the mouse genome, and human FoxM1a with the exon 
9  inclusion  does  not  encode  a  functional  FoxM1a 
protein; the enhancement of mouse FoxM1 expression 
b y   S R p 2 0   t h e r e f o r e   p r e s u m a b l y   o c c u r s   b y   t r a n s c r i p-
tion  through  an  indirect  mechanism.  On  the  other 
hand, the enhancement of human FoxM1 expression 
b y   S R p 2 0   m i g h t   o c c u r   t h r o u g h   t h e   r e g u l a t i o n   o f   RNA 
splicing, most likely by promoting the exclusion of 
FoxM1 exon 9. Nevertheless, the effects of SRp20 on 
F o x M 1 ,   P L K 1 ,   a n d   C d c 2 5 B   e x p r e s s i o n   a r e   o n e   m e-
chanism by which SRp20 regulates cell proliferation 
and oncogenesis. 
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Figures 
 
Figure S1. Increased SRp20 expression in 
o t h e r   s o f t   t i s s u e   t u m o r s   s h o w n   b y   i m-
munohistochemistry with the SRp20 7B4 
antibody. SRp20 expression was compared 
in  paired  normal  and  tumor  tissues  in-
cluding  blood  vessels,  nerves,  and  fatty 
tissues, grouped by the vertical l i n e s   o n   t h e  
right.  Leiomyosarcoma,  fibrous  histiocy-
toma,  and  synovial  sarcoma  with  strong 
SRp20  expression  are  also  included  as 
additional examples. See other details in 
Figure 2. Int. J. Biol. Sci. 2010, 6 
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Figure S2. SRp20 expression is essential for tumor cell growth. SRp20 was k n o c k e d   d o w n   b y   R N A i   a s   d e s c r i b e d   i n   F i g u r e  
5B, and cell growth was measured in cervical cancer cell lines CaSki (A) and C33A (B), kidney cancer cell line 786-O (C), 
B-cell lymphoma cell lines JSC-1   ( D)   a n d   B C B L -1   ( E) ,   a n d   U 2 O S   c e l l s   ( F) .   T h e   k n o c k d o w n   e f ficiency in individual cell lines on 
t h e   i n d i c a t e d   d a y s   ( D 2 ,   D 4 ,   a n d   D 6 )   i n   A-E o r   o n   d a y   4   i n   F was estimated by Western blot and is shown on the top left of 
e a c h   l i n e   g r a p h .   h n R N P   K   s e r v e d   a s   a   c o n t r o l   f o r   s a m p l e   l o a d i n g .   A r r o w s   i n d i c a t e   d a y s   a f t e r   c e l l   passage when RNAi was 
p e r f o r m e d .   P o o l e d   S R p 2 0   s i R N A s   D -01 to D-04 (Figure 5A) were used at a final concentration of 40 nM in A-E, and a single 
D-03 SRp20 siRNA (Figure 5A) was used at a final concentration of 20 nM in F. Data are shown as means ± SD from two 
separate experiments, each in duplicate. (G) YB-1 or hnRNP U knockdown had no effect on HeLa cell growth. Int. J. Biol. Sci. 2010, 6 
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Figure S3. Diagrams of FoxM1, Cdc25B and PLK1 pre-mRNA structures and splice directions and SRp20 regulation of 
PLK1 expression by qRT-PCR analysis. (A)   H u m a n   F o x M 1   e x p r e s s e s   3   R N A   i s o f o r m s   b y   a l t e r n a t i v e   R N A   s p l i c i n g   i n v o l v i n g  
exons 6 and 9. FoxM1a, with 10 exons (boxes) and 9 introns (lines between boxes), is a full-length RNA encoding minimal Int. J. Biol. Sci. 2010, 6 
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or no detectable protein [37,38]. Mouse FoxM1 e x p r e s s e s   a   m a j o r   R N A   i s o f o r m   w i t h   8   e x o n s .   M o u s e   F o x M 1   h a s   n o  
equivalent sequences to human FoxM1 exon 9 and its exon 8 is a fusion of the human FoxM1 exon 8 and 10 sequence s   [ 62]. 
(B)   H u m a n   C d c 2 5 B   e x p r e s s   3   R N A   i s o f o r m s   b y   a l t e r n a t i v e   R N A   s p l i c i n g   i n v o l v ing exons 2 and 6 [63]. The isoform 2 of 
C d c 2 5 B ,   w i t h   1 6   e x o n s ,   i s   a   m a j o r   i s o f o r m   c o n t a i n i n g   a n   a l t e r n a t i v e l y   s p l i c e d   e x o n   2 .   M o u s e   C d c 2 5 B   e x p r e s s e s   a   m a j o r   R N A  
i s o f o r m   w i t h   1 6   e x o n s .   ( C) Both human and mouse PLK1 contain 10 exons with no reported alternative RNA splicing. Short 
lines above or below exons are the primers used for RT-P C R   a n a l y s e s   o f   F o x M 1 ,   C d c 2 5 B   a n d   P L K 1   m R N A s .   D r a w i n g s   a r e  
not to scale. (D) SRp20 regulates expression of PLK1. Total RNAs were purified from U2OS cells with or without SRp20 
knockdown by using Ambion siRNA s12732, or from HeLa cells with or without SRp20 knockdown by using pooled 
Dharmacon siRNAs. TaqMan probes for human PLK1 and 18S rRNA detection were used for qRT-PCR. 